Literature DB >> 21602493

Inflammatory cytokines IL-32 and IL-17 have common signaling intermediates despite differential dependence on TNF-receptor 1.

Emily Turner-Brannen1, Ka-Yee Grace Choi, Ryan Arsenault, Hani El-Gabalawy, Scott Napper, Neeloffer Mookherjee.   

Abstract

Cytokines IL-32 and IL-17 are emerging as critical players in the pathophysiology of immune-mediated chronic inflammatory diseases. It has been speculated that the molecular mechanisms governing IL-32- and IL-17-mediated cellular responses are differentially dependent on the TNF pathway. In this study, kinome analysis demonstrated that following stimulation with cytokine IL-32, but not IL-17, there was increased phosphorylation of a peptide target corresponding to TNF-R1. Consistent with this observation, blocking TNF-R1 resulted in a suppression of IL-32-induced downstream responses, indicating that IL-32-mediated activity may be dependent on TNF-R1. In contrast, blocking TNF-R1 did not affect IL-17-induced downstream responses. Kinome analysis also implicated p300 (transcriptional coactivator) and death-associated protein kinase-1 (DAPK-1) as signaling intermediates for both IL-32 and IL-17. Phosphorylation of p300 and DAPK-1 upon stimulation with either IL-32 or IL-17 was confirmed by immunoblots. The presence of common targets was supported by results demonstrating similar downstream responses induced in the presence of IL-32 and IL-17, such as transcriptional responses and the direct activation of NF-κB. Furthermore, knockdown of p300 and DAPK-1 altered downstream responses induced by IL-32 and IL-17, and impacted certain cellular responses induced by TNF-α and IL-1β. We hypothesize that p300 and DAPK-1 represent nodes where the inflammatory networks of IL-32 and IL-17 overlap, and that these proteins would affect both TNF-R1-dependent and -independent pathways. Therefore, p300 and DAPK-1 are viable potential therapeutic targets for chronic inflammatory diseases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21602493     DOI: 10.4049/jimmunol.1002306

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  20 in total

1.  c-Jun N-terminal kinase and Akt signalling pathways regulating tumour necrosis factor-α-induced interleukin-32 expression in human lung fibroblasts: implications in airway inflammation.

Authors:  Dagen Li; Dapeng Chen; Xuemei Zhang; Hong Wang; Zixin Song; Wenchun Xu; Yujuan He; Yibing Yin; Ju Cao
Journal:  Immunology       Date:  2015-02       Impact factor: 7.397

Review 2.  Novel insights into the biology of interleukin-32.

Authors:  Leo A B Joosten; Bas Heinhuis; Mihai G Netea; Charles A Dinarello
Journal:  Cell Mol Life Sci       Date:  2013-03-06       Impact factor: 9.261

3.  Human cathelicidin LL-37 and its derivative IG-19 regulate interleukin-32-induced inflammation.

Authors:  Ka-Yee G Choi; Scott Napper; Neeloffer Mookherjee
Journal:  Immunology       Date:  2014-09       Impact factor: 7.397

4.  Increased plasma interleukin-32 expression in patients with neuromyelitis optica.

Authors:  Honghao Wang; Kai Wang; Conghui Wang; Fangcheng Xu; Wei Qiu; Xueqiang Hu
Journal:  J Clin Immunol       Date:  2012-11-21       Impact factor: 8.317

5.  Impact of intra-tumoral IL17A and IL32 gene expression on T-cell responses and lymph node status in breast cancer patients.

Authors:  Shreyas Bhat; Nilesh Gardi; Sujata Hake; Nirupama Kotian; Sharada Sawant; Sadhana Kannan; Vani Parmar; Sangeeta Desai; Amit Dutt; Narendra N Joshi
Journal:  J Cancer Res Clin Oncol       Date:  2017-05-03       Impact factor: 4.553

6.  IL-32 and IL-17 interact and have the potential to aggravate osteoclastogenesis in rheumatoid arthritis.

Authors:  Young-Mee Moon; Bo-Young Yoon; Yang-Mi Her; Hye-Joa Oh; Jae-Seon Lee; Kyoung-Woon Kim; Seon-Yeong Lee; Yun-Ju Woo; Kyung-Su Park; Sung-Hwan Park; Ho-Youn Kim; Mi-La Cho
Journal:  Arthritis Res Ther       Date:  2012-11-13       Impact factor: 5.156

7.  Overt IL-32 isoform expression at intestinal level during HIV-1 infection is negatively regulated by IL-17A.

Authors:  Etiene Moreira Gabriel; Tomas Raul Wiche Salinas; Annie Gosselin; Etienne Larouche-Anctil; Madeleine Durand; Alan L Landay; Mohamed El-Far; Cécile L Tremblay; Jean-Pierre Routy; Petronela Ancuta
Journal:  AIDS       Date:  2021-10-01       Impact factor: 4.632

8.  MicroRNA-26b inhibits cell proliferation and cytokine secretion in human RASF cells via the Wnt/GSK-3β/β-catenin pathway.

Authors:  Jiling Sun; Peng Yan; Yuanzheng Chen; Yang Chen; Jianxun Yang; Guangyue Xu; Haijun Mao; Yong Qiu
Journal:  Diagn Pathol       Date:  2015-06-19       Impact factor: 2.644

Review 9.  Death-associated protein kinase: A molecule with functional antagonistic duality and a potential role in inflammatory bowel disease (Review).

Authors:  Sara Steinmann; Kristina Scheibe; Katharina Erlenbach-Wuensch; Clemens Neufert; Regine Schneider-Stock
Journal:  Int J Oncol       Date:  2015-05-11       Impact factor: 5.650

10.  Ultrashort cationic lipopeptides and lipopeptoids selectively induce cytokine production in macrophages.

Authors:  Brandon Findlay; Neeloffer Mookherjee; Frank Schweizer
Journal:  PLoS One       Date:  2013-02-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.